Medline Inc. Class A (MDLN)
NASDAQ: MDLNHealthcareMedical Instruments & SuppliesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 35.45 0.00%
MDLN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $47.70B
- P/E (TTM)
- 88.63
- Forward P/E
- 22.48
- EPS (TTM)
- $0.40
- Dividend yield
- None
- 52-week range
- 31.49 – 50.88
- Day range
- 35.21 – 35.97
- Volume / Avg
- 4.39M / 7.61M
- Beta
- —
- Shares outstanding
- 877.35M
- Next earnings
- Nov 4, 2026
52-week range
MDLN stock today
Medline (MDLN) closed at $35.45 on Oct 7, down 0.28% (-$0.10), versus the S&P 500's 0.22% decline. Shares are 30.3% below their 52-week high of $50.88, set on Feb 25, 2026 and 12.6% above the 52-week low of $31.49, in the middle of the past year's range. MDLN is down 15.3% year to date, underperforming the S&P 500 (+14.0%).
At 88.6x trailing earnings, Medline trades above the peer-group median of 41.9x. Its forward P/E of 22.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Medline's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Medline
Company profileMedline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- CEO
- Mr. James M. Boyle
- Headquarters
- Northfield, IL
- Employees
- 45,000
- IPO year
- 2025
- Website
- medline.com
Financial highlights
Full financialsIn fiscal 2025, Medline generated $28.43 billion in revenue. Net income was $1.16 billion (+0.5% year over year), for a net margin of 4.1% versus a median of 2.8% in the prior 3 years. Gross margin was 26.4% and operating margin 7.8%.
| Fiscal year | FY 2025 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Revenue | $28.43B | — | $25.51B | $23.23B |
| Growth | — | — | +9.80% | — |
| Net income | $1.16B | $1.15B | $1.16B | $234.00M |
| EPS (diluted) | $-0.01 | — | — | — |
Analyst forecast
ForecastConsensus (27 analysts)
buy
Avg. price target
$44.50+25.53%
- Strong buy 7
- Buy 16
- Hold 4
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $0.32
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $0.07 vs —
MDLN news
All MDLN newsMedline peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BDXBecton Dickinson and Company | 180.17 | -0.07% | $49.07B | vs MDLN |
| RMDResMed Inc. | 226.09 | +2.45% | $31.80B | vs MDLN |
| ALCAlcon Inc. | 63.02 | -0.28% | $30.46B | vs MDLN |
| WSTWest Pharmaceutical Services Inc. | 366.37 | -1.68% | $25.78B | vs MDLN |
| SOLVSolventum Corporation | 85.87 | -1.34% | $14.62B | vs MDLN |
| BAXBaxter International Inc. | 23.97 | -1.60% | $12.39B | vs MDLN |
| RGENRepligen Corporation | 167.22 | -4.37% | $10.62B | vs MDLN |
| COOThe Cooper Companies Inc. | 54.75 | -2.98% | $10.41B | vs MDLN |
Indexes, lists and sector
Appears in lists
Medline stock FAQ
What is Medline's stock price today?
MDLN last traded at $35.45 as of Oct 7, 4:00 PM EDT, down 0.28% on the day. Prices are delayed at least 15 minutes.
When is Medline's next earnings date?
Medline is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $0.32.
What is MDLN's P/E ratio?
MDLN trades at a trailing P/E ratio of 88.63 and a forward P/E of 22.48, compared with a median of 41.9 for its closest peers.
Who is Medline's CEO?
Mr. James M. Boyle is the chief executive officer of Medline Inc. Class A, which has about 45,000 employees.
What is the MDLN 52-week high?
The 52-week high for MDLN is $50.88 and the 52-week low is $31.49. The stock is currently 30.3% below its high.